Literature DB >> 10519927

Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.

L S Wyatt1, S S Whitehead, K A Venanzi, B R Murphy, B Moss.   

Abstract

Intranasal and intramuscular immunizations of mice with the highly attenuated MVA strain of vaccinia virus expressing the respiratory syncytial virus (RSV) F or G glycoprotein induced higher RSV antibody titers than those achieved by infection with RSV and greatly restricted the replication of RS challenge virus in both the upper and lower respiratory tracts. In addition, a recombinant MVA expressing both RSV F and G was stable and was as immunogenic as a combination of two single recombinant viruses. The levels of antibodies to RSV F and G, induced by previous intranasal infection with attenuated RSV, were boosted by intramuscular immunization with recombinant MVA. These data support further development of recombinant MVA as a RSV vaccine.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10519927     DOI： 10.1016/s0264-410x(99)00257-1

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  32 in total

1.  Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys.

Authors:  D H Barouch; A Craiu; S Santra; M A Egan; J E Schmitz; M J Kuroda; T M Fu; J H Nam; L S Wyatt; M A Lifton; G R Krivulka; C E Nickerson; C I Lord; B Moss; M G Lewis; V M Hirsch; J W Shiver; N L Letvin
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.

Authors:  Linda S Wyatt; Patricia L Earl; Jennifer Vogt; Leigh Anne Eller; Dev Chandran; Jinyan Liu; Harriet L Robinson; Bernard Moss
Journal:  Vaccine       Date:  2007-12-03       Impact factor: 3.641

3.  Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.

Authors:  Simone Hornemann; Olof Harlin; Caroline Staib; Sigrid Kisling; Volker Erfle; Bernd Kaspers; Georg Häcker; Gerd Sutter
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

4.  Recombinant simian varicella viruses expressing respiratory syncytial virus antigens are immunogenic.

Authors:  Toby M Ward; Vicki Traina-Dorge; Kara A Davis; Wayne L Gray
Journal:  J Gen Virol       Date:  2008-03       Impact factor: 3.891

5.  Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.

Authors:  Hoyin Mok; Sujin Lee; Thomas J Utley; Bryan E Shepherd; Vasiliy V Polosukhin; Martha L Collier; Nancy L Davis; Robert E Johnston; James E Crowe
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

Review 6.  Respiratory syncytial virus vaccine development.

Authors:  Yoshihiko Murata
Journal:  Clin Lab Med       Date:  2009-12       Impact factor: 1.935

7.  Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.

Authors:  M Magdalena Gherardi; José Luis Nájera; Eva Pérez-Jiménez; Susana Guerra; Adolfo García-Sastre; Mariano Esteban
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

8.  Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines.

Authors:  Patricia L Earl; Catherine Cotter; Bernard Moss; Thomas VanCott; Jeffrey Currier; Leigh Anne Eller; Francine McCutchan; Deborah L Birx; Nelson L Michael; Mary A Marovich; Merlin Robb; Josephine H Cox
Journal:  Vaccine       Date:  2009-08-03       Impact factor: 3.641

Review 9.  Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.

Authors:  Matthew R Olson; Steven M Varga
Journal:  Expert Rev Vaccines       Date:  2008-10       Impact factor: 5.217

10.  Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.

Authors:  Linda S Wyatt; Igor M Belyakov; Patricia L Earl; Jay A Berzofsky; Bernard Moss
Journal:  Virology       Date:  2007-11-28       Impact factor: 3.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.